IN2012DN00754A - - Google Patents
Download PDFInfo
- Publication number
- IN2012DN00754A IN2012DN00754A IN754DEN2012A IN2012DN00754A IN 2012DN00754 A IN2012DN00754 A IN 2012DN00754A IN 754DEN2012 A IN754DEN2012 A IN 754DEN2012A IN 2012DN00754 A IN2012DN00754 A IN 2012DN00754A
- Authority
- IN
- India
- Prior art keywords
- compounds
- antagonists
- lpa
- medicaments
- diseases
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 abstract 3
- 239000005557 antagonist Substances 0.000 abstract 2
- 230000001419 dependent effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D261/14—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6527—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and oxygen atoms as the only ring hetero atoms
- C07F9/653—Five-membered rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Biochemistry (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyridine Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US23128209P | 2009-08-04 | 2009-08-04 | |
PCT/US2010/044284 WO2011017350A2 (en) | 2009-08-04 | 2010-08-03 | Compounds as lysophosphatidic acid receptor antagonists |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2012DN00754A true IN2012DN00754A (nl) | 2015-06-19 |
Family
ID=43544907
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN754DEN2012 IN2012DN00754A (nl) | 2009-08-04 | 2010-08-03 |
Country Status (6)
Country | Link |
---|---|
US (1) | US8592402B2 (nl) |
EP (1) | EP2462128B1 (nl) |
JP (1) | JP2013501064A (nl) |
CN (1) | CN102574822A (nl) |
IN (1) | IN2012DN00754A (nl) |
WO (1) | WO2011017350A2 (nl) |
Families Citing this family (64)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8455499B2 (en) | 2008-12-11 | 2013-06-04 | Amira Pharmaceuticals, Inc. | Alkyne antagonists of lysophosphatidic acid receptors |
GB2466121B (en) | 2008-12-15 | 2010-12-08 | Amira Pharmaceuticals Inc | Antagonists of lysophosphatidic acid receptors |
GB2470833B (en) | 2009-06-03 | 2011-06-01 | Amira Pharmaceuticals Inc | Polycyclic antagonists of lysophosphatidic acid receptors |
EP2462128B1 (en) | 2009-08-04 | 2016-09-21 | Amira Pharmaceuticals, Inc. | Compounds as lysophosphatidic acid receptor antagonists |
GB2474120B (en) | 2009-10-01 | 2011-12-21 | Amira Pharmaceuticals Inc | Compounds as Lysophosphatidic acid receptor antagonists |
GB2474748B (en) | 2009-10-01 | 2011-10-12 | Amira Pharmaceuticals Inc | Polycyclic compounds as lysophosphatidic acid receptor antagonists |
PE20140879A1 (es) | 2010-12-07 | 2014-08-06 | Amira Pharmaceuticals Inc | Antagonistas del receptor de acido lisofosfatidico para el tratamiento de fibrosis |
US8541587B2 (en) | 2011-04-05 | 2013-09-24 | Amira Pharmaceuticals, Inc. | Lysophosphatidic acid receptor antagonists |
WO2012138648A1 (en) * | 2011-04-06 | 2012-10-11 | Irm Llc | Compositions and methods for modulating lpa receptors |
CA2844469C (en) * | 2011-08-08 | 2019-08-20 | Merck Patent Gmbh | N-(benzimimdazol-2-yl)-cyclopropane carboxamides as lysophosphatidic acid antagonists |
MX2014001732A (es) * | 2011-08-15 | 2014-07-09 | Intermune Inc | Antagonistas del receptor de acido lisofosfatidico. |
CN103987858A (zh) | 2011-11-22 | 2014-08-13 | 英特芒尼公司 | 诊断和治疗特发性肺纤维化的方法 |
TWI633087B (zh) | 2012-06-13 | 2018-08-21 | 赫孚孟拉羅股份公司 | 新穎二氮雜螺環烷及氮雜螺環烷 |
IN2014DN09347A (nl) * | 2012-06-20 | 2015-07-17 | Hoffmann La Roche | |
WO2014026039A2 (en) * | 2012-08-09 | 2014-02-13 | Neuropore Therapies, Inc. | Aryl-and heteroaryl-substituted benzene derivatives as modulators of pi3-kinase signalling pathways |
UA116547C2 (uk) | 2012-09-25 | 2018-04-10 | Ф. Хоффманн-Ля Рош Аг | Біциклічні похідні |
JP6176258B2 (ja) | 2012-12-28 | 2017-08-09 | 宇部興産株式会社 | ハロゲン置換へテロ環化合物 |
WO2014113485A1 (en) * | 2013-01-15 | 2014-07-24 | Intermune, Inc. | Lysophosphatidic acid receptor antagonists |
AR095079A1 (es) | 2013-03-12 | 2015-09-16 | Hoffmann La Roche | Derivados de octahidro-pirrolo[3,4-c]-pirrol y piridina-fenilo |
SG10201803833WA (en) | 2013-03-15 | 2018-06-28 | Epigen Biosciences Inc | Heterocyclic compounds useful in the treatment of disease |
EA038294B1 (ru) * | 2013-05-24 | 2021-08-05 | Эпиджен Байосайенсиз, Инк. | Гетероциклические соединения, применимые в лечении заболеваний |
GB201314926D0 (en) * | 2013-08-20 | 2013-10-02 | Takeda Pharmaceutical | Novel Compounds |
EA201691044A1 (ru) | 2013-11-26 | 2016-09-30 | Ф. Хоффманн-Ля Рош Аг | Новый октагидро-циклобута[1,2-c;3,4-c']дипиррол-2-ил |
PE20161134A1 (es) | 2014-03-26 | 2016-10-29 | Hoffmann La Roche | Compuestos biciclicos como inhibidores de la produccion de autotaxina (atx) y acido lisofosfatidico (lpa) |
JP6554481B2 (ja) | 2014-03-26 | 2019-07-31 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | オートタキシン(atx)及びリゾホスファチジン酸(lpa)産生の阻害剤としての縮合[1,4]ジアゼピン化合物 |
JP6616821B2 (ja) | 2014-04-04 | 2019-12-04 | エックス−アールエックス, インコーポレイテッド | オートタキシンの置換スピロ環式阻害剤 |
CN107205972A (zh) * | 2014-04-23 | 2017-09-26 | X-Rx股份有限公司 | 自分泌运动因子的取代的n‑(2‑(氨基)‑2‑氧代乙基)苯甲酰胺抑制剂及它们的制备和在治疗lpa‑依赖的或lpa‑介导的疾病中的用途 |
JP6579103B2 (ja) | 2014-06-27 | 2019-09-25 | 宇部興産株式会社 | ハロゲン置換へテロ環化合物の塩 |
WO2016046782A1 (en) * | 2014-09-26 | 2016-03-31 | Glenmark Pharmaceuticals S.A. | Imidazole biaryl compounds as s-nitrosoglutathione reductase inhibitors |
MA41898A (fr) | 2015-04-10 | 2018-02-13 | Hoffmann La Roche | Dérivés de quinazolinone bicyclique |
LT3288379T (lt) | 2015-05-01 | 2022-02-25 | Onl Therapeutics, Inc. | Peptidų kompozicijos ir naudojimo būdai |
AU2016270373A1 (en) | 2015-06-05 | 2018-01-04 | Vertex Pharmaceuticals Incorporated | Triazoles for the treatment of demyelinating diseases |
UA123362C2 (uk) | 2015-09-04 | 2021-03-24 | Ф. Хоффманн-Ля Рош Аг | Феноксиметильні похідні |
KR20180054635A (ko) | 2015-09-24 | 2018-05-24 | 에프. 호프만-라 로슈 아게 | 오토탁신(atx) 억제제로서 이환형 화합물 |
MX2017015034A (es) | 2015-09-24 | 2018-04-13 | Hoffmann La Roche | Nuevos compuestos biciclicos como inhibidores duales de autotaxina (atx)/anhidrasa carbonica (ca). |
KR20180054634A (ko) | 2015-09-24 | 2018-05-24 | 에프. 호프만-라 로슈 아게 | 이중 오토탁신(atx)/탄산 무수화효소(ca) 억제제로서 신규한 이환형 화합물 |
JP6846414B2 (ja) | 2015-09-24 | 2021-03-24 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | Atx阻害剤としての二環式化合物 |
WO2018106643A1 (en) | 2016-12-06 | 2018-06-14 | Vertex Pharmaceuticals Incorporated | Heterocyclic azoles for the treatment of demyelinating diseases |
WO2018106641A1 (en) | 2016-12-06 | 2018-06-14 | Vertex Pharmaceuticals Incorporated | Pyrazoles for the treatment of demyelinating diseases |
WO2018106646A1 (en) | 2016-12-06 | 2018-06-14 | Vertex Pharmaceuticals Incorporated | Aminotriazoles for the treatment of demyelinating diseases |
CR20190423A (es) | 2017-03-16 | 2019-11-01 | Hoffmann La Roche | Nuevos compuestos biciclícos como inhibidores dobles de atx/ca |
CN110382484B (zh) | 2017-03-16 | 2022-12-06 | 豪夫迈·罗氏有限公司 | 新的作为atx抑制剂的二环化合物 |
KR102639231B1 (ko) | 2017-10-30 | 2024-02-22 | 뉴로포레 테라피스, 인코포레이티드 | 치환된 페닐 설폰일 페닐 트리아졸 싸이온 및 이의 용도 |
US11352345B2 (en) | 2017-12-19 | 2022-06-07 | Bristol-Myers Squibb Company | Cyclohexyl acid pyrazole azoles as LPA antagonists |
WO2019126093A1 (en) | 2017-12-19 | 2019-06-27 | Bristol-Myers Squibb Company | Cyclohexyl acid triazole azines as lpa antagonists |
WO2019126086A1 (en) * | 2017-12-19 | 2019-06-27 | Bristol-Myers Squibb Company | Cyclohexyl acid isoxazole azines as lpa antagonists |
ES2944304T3 (es) | 2017-12-19 | 2023-06-20 | Bristol Myers Squibb Co | Pirazol azinas de ácido ciclohexílico como antagonistas de LPA |
EP3728196B1 (en) * | 2017-12-19 | 2023-04-05 | Bristol-Myers Squibb Company | Pyrazole o-linked carbamoyl cyclohexyl acids as lpa antagonists |
CN112189010A (zh) | 2017-12-19 | 2021-01-05 | 百时美施贵宝公司 | 作为lpa拮抗剂的三唑n-连接的氨基甲酰基环己基酸 |
EA202091505A1 (ru) | 2017-12-19 | 2020-09-22 | Бристол-Маерс Сквибб Компани | Триазолазолы циклогексильной кислоты в качестве антагонистов lpa |
KR20200101957A (ko) * | 2017-12-19 | 2020-08-28 | 브리스톨-마이어스 스큅 컴퍼니 | Lpa 길항제로서의 이속사졸 o-연결된 카르바모일 시클로헥실 산 |
CN112074515A (zh) * | 2017-12-19 | 2020-12-11 | 百时美施贵宝公司 | 作为lpa拮抗剂的环己基酸异噁唑唑类 |
US11447475B2 (en) | 2017-12-19 | 2022-09-20 | Bristol-Myers Squibb Company | Isoxazole N-linked carbamoyl cyclohexyl acids as LPA antagonists |
AU2018388482A1 (en) | 2017-12-19 | 2020-07-30 | Bristol-Myers Squibb Company | Pyrazole N-linked carbamoyl cyclohexyl acids as LPA antagonists |
KR20220024549A (ko) | 2019-06-18 | 2022-03-03 | 브리스톨-마이어스 스큅 컴퍼니 | Lpa 길항제로서의 이속사졸 카르복실산 |
US20220235026A1 (en) | 2019-06-18 | 2022-07-28 | Bristol-Myers Squibb Company | Triazole carboxylic acids as lpa antagonists |
EP3986553A1 (en) * | 2019-06-18 | 2022-04-27 | Bristol-Myers Squibb Company | Cyclobutyl carboxylic acids as lpa antagonists |
US20230097871A1 (en) * | 2019-07-30 | 2023-03-30 | Taisho Pharmaceutical Co., Ltd. | Urea compound for antagonizing lpa1 receptor |
EP4058144A1 (en) | 2019-11-15 | 2022-09-21 | Gilead Sciences, Inc. | Triazole carbamate pyridyl sulfonamides as lpa receptor antagonists and uses thereof |
EP4161936A1 (en) | 2020-06-03 | 2023-04-12 | Gilead Sciences, Inc. | Lpa receptor antagonists and uses thereof |
JP7490088B2 (ja) | 2020-06-03 | 2024-05-24 | ギリアード サイエンシーズ, インコーポレイテッド | Lpa受容体アンタゴニスト及びその使用 |
US20230250093A1 (en) * | 2020-07-16 | 2023-08-10 | Chiesi Farmaceutici S.P.A. | Amido cyclohexane acid derivatives as lpa receptor inhibitors |
WO2022240879A1 (en) | 2021-05-11 | 2022-11-17 | Gilead Sciences, Inc. | Lpa receptor antagonists and uses thereof |
US11939318B2 (en) | 2021-12-08 | 2024-03-26 | Gilead Sciences, Inc. | LPA receptor antagonists and uses thereof |
Family Cites Families (68)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4229447A (en) | 1979-06-04 | 1980-10-21 | American Home Products Corporation | Intraoral methods of using benzodiazepines |
US5116817A (en) | 1982-12-10 | 1992-05-26 | Syntex (U.S.A.) Inc. | LHRH preparations for intranasal administration |
US4476116A (en) | 1982-12-10 | 1984-10-09 | Syntex (U.S.A.) Inc. | Polypeptides/chelating agent nasal compositions having enhanced peptide absorption |
US4596795A (en) | 1984-04-25 | 1986-06-24 | The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services | Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives |
EP0230654B1 (en) | 1985-12-28 | 1992-03-18 | Sumitomo Pharmaceuticals Company, Limited | Sustained pulsewise release pharmaceutical preparation |
US4755386A (en) | 1986-01-22 | 1988-07-05 | Schering Corporation | Buccal formulation |
US5739136A (en) | 1989-10-17 | 1998-04-14 | Ellinwood, Jr.; Everett H. | Intraoral dosing method of administering medicaments |
US5017381A (en) | 1990-05-02 | 1991-05-21 | Alza Corporation | Multi-unit pulsatile delivery system |
US5229135A (en) | 1991-11-22 | 1993-07-20 | Prographarm Laboratories | Sustained release diltiazem formulation |
US5612359A (en) | 1994-08-26 | 1997-03-18 | Bristol-Myers Squibb Company | Substituted biphenyl isoxazole sulfonamides |
GB9523946D0 (en) | 1995-11-23 | 1996-01-24 | Bayer Ag | Leukotriene antagonistic benzoic acid derivatives |
US5837284A (en) | 1995-12-04 | 1998-11-17 | Mehta; Atul M. | Delivery of multiple doses of medications |
ES2196396T3 (es) | 1996-12-23 | 2003-12-16 | Bristol Myers Squibb Pharma Co | Compuestos heteroaromaticos de 5 miembros conteniendo oxigeno o azufre como inhibidores del factor xa. |
JP3237608B2 (ja) | 1997-04-21 | 2001-12-10 | 住友製薬株式会社 | イソキサゾール誘導体 |
US5840329A (en) | 1997-05-15 | 1998-11-24 | Bioadvances Llc | Pulsatile drug delivery system |
US6391452B1 (en) | 1997-07-18 | 2002-05-21 | Bayer Corporation | Compositions for nasal drug delivery, methods of making same, and methods of removing residual solvent from pharmaceutical preparations |
WO2000059902A2 (en) | 1999-04-02 | 2000-10-12 | Du Pont Pharmaceuticals Company | Aryl sulfonyls as factor xa inhibitors |
DK1258484T3 (da) | 2000-02-18 | 2009-04-20 | Kyowa Hakko Kirin Co Ltd | Nye isoxazol- og thiazolforbindelser og anvendelse deraf som lægemidler |
AU2001273040A1 (en) | 2000-06-27 | 2002-01-08 | Du Pont Pharmaceuticals Company | Factor xa inhibitors |
WO2002062389A1 (fr) | 2001-02-08 | 2002-08-15 | Ono Pharmaceutical Co., Ltd. | Remedes pour des maladies urinaires contenant des agents de regulation du recepteur de lpa |
US7521192B2 (en) | 2001-04-18 | 2009-04-21 | Rigel Pharmaceuticals, Inc. | EDG: modulators of lymphocyte activation and migration |
WO2003007991A1 (fr) | 2001-07-17 | 2003-01-30 | Ono Pharmaceutical Co., Ltd. | Regulateurs de la secretion de suc pancreatique comprenant un agent de regulation du recepteur a lpa |
MY151199A (en) | 2001-11-02 | 2014-04-30 | Rigel Pharmaceuticals Inc | Substituted diphenyl heterocycles useful for treating hcv infection |
AU2002367129A1 (en) | 2001-12-25 | 2003-07-15 | Ajinomoto Co., Inc. | Organ fibrosis inhibitors |
US20050113283A1 (en) | 2002-01-18 | 2005-05-26 | David Solow-Cordero | Methods of treating conditions associated with an EDG-4 receptor |
WO2003062392A2 (en) | 2002-01-18 | 2003-07-31 | Ceretek Llc | Methods of treating conditions associated with an edg receptor |
US20050101518A1 (en) | 2002-01-18 | 2005-05-12 | David Solow-Cordero | Methods of treating conditions associated with an EDG-2 receptor |
US20050261298A1 (en) | 2002-01-18 | 2005-11-24 | David Solow-Cordero | Methods of treating conditions associated with an Edg-7 receptor |
US20040014662A1 (en) | 2002-05-08 | 2004-01-22 | Per Lindquist | Modulation of neural stem cells and neural progenitor cells |
US7229987B2 (en) | 2002-05-13 | 2007-06-12 | Eli Lilly And Company | Multicyclic compounds for use as melanin concentrating hormone antagonists in the treatment of obesity and diabetes |
WO2003099765A1 (fr) | 2002-05-28 | 2003-12-04 | Ono Pharmaceutical Co., Ltd. | Derive de $g(b)-alanine et utilisation correspondante |
WO2004002530A1 (ja) | 2002-06-26 | 2004-01-08 | Ono Pharmaceutical Co., Ltd. | 慢性疾患治療剤 |
AU2003241836A1 (en) | 2002-10-03 | 2004-04-23 | Ono Pharmaceutical Co., Ltd. | Lpa receptor antagonists |
AU2003294315A1 (en) | 2002-11-19 | 2004-06-15 | Amgen Inc. | Amplified genes involved in cancer |
US20040167132A1 (en) | 2003-01-16 | 2004-08-26 | Geetha Shankar | Methods of treating conditions associted with an Edg-2 receptor |
US20050065194A1 (en) | 2003-01-16 | 2005-03-24 | Geetha Shankar | Methods of treating conditions associated with an Edg-2 receptor |
US20040192739A1 (en) | 2003-01-16 | 2004-09-30 | David Solow-Cordero | Methods of treating conditions associated with an Edg-2 receptor |
US7135469B2 (en) | 2003-03-18 | 2006-11-14 | Bristol Myers Squibb, Co. | Linear chain substituted monocyclic and bicyclic derivatives as factor Xa inhibitors |
WO2004099164A1 (en) | 2003-05-02 | 2004-11-18 | Rigel Pharmaceuticals, Inc. | Substituted diphenyl isoxazoles, pyrazoles and oxadiazoles useful for treating hcv infection |
CN1791592B (zh) | 2003-05-19 | 2012-07-04 | Irm责任有限公司 | 免疫抑制剂化合物和组合物 |
WO2007016784A1 (en) | 2005-08-11 | 2007-02-15 | Merck Frosst Canada Ltd. | Novel substituted 1,2,3-tπazolylmethyl-benzothiophene or -indole and their use as leukotπene biosynthesis inhibitors |
WO2005012269A1 (ja) * | 2003-08-05 | 2005-02-10 | Ajinomoto Co., Inc. | 新規アゾール化合物 |
JP4766384B2 (ja) | 2003-12-19 | 2011-09-07 | 小野薬品工業株式会社 | リゾホスファチジン酸受容体拮抗作用を有する化合物およびその用途 |
DE10360369A1 (de) | 2003-12-22 | 2005-07-14 | Bayer Cropscience Ag | Amide |
JP2006096712A (ja) | 2004-09-30 | 2006-04-13 | Senju Pharmaceut Co Ltd | Lpa受容体拮抗剤を含有する角膜知覚改善剤 |
AR055041A1 (es) | 2005-03-23 | 2007-08-01 | Merck Frosst Canada Ltd | Tiadiazoles y oxadiazoles como inhibidores de la sintesis de leucotrienos. composiciones farmaceuticas. |
US20080306124A1 (en) | 2005-06-08 | 2008-12-11 | Rainer Albert | Polycyclic Oxadiazoles or I Soxazoles and Their Use as Sip Receptor Ligands |
WO2007007588A1 (ja) | 2005-07-08 | 2007-01-18 | Ono Pharmaceutical Co., Ltd. | 平面性を有する環状基を母核とする化合物 |
AU2006283175A1 (en) | 2005-08-23 | 2007-03-01 | Irm Llc | Immunosuppressant compounds and compositions |
US7405302B2 (en) | 2005-10-11 | 2008-07-29 | Amira Pharmaceuticals, Inc. | 5-lipoxygenase-activating protein (FLAP) inhibitors |
US20070219206A1 (en) | 2005-11-04 | 2007-09-20 | Amira Pharmaceuticals, Inc. | 5-lipoxygenase-activating protein (flap) inhibitors |
US20070225285A1 (en) | 2005-11-04 | 2007-09-27 | Amira Pharmaceuticals, Inc. | 5-lipoxygenase-activating protein (flap) inhibitors |
US7977359B2 (en) | 2005-11-04 | 2011-07-12 | Amira Pharmaceuticals, Inc. | 5-lipdxygenase-activating protein (FLAP) inhibitors |
CA2636043A1 (en) | 2006-01-23 | 2007-08-02 | Amira Pharmaceuticals, Inc. | Tricyclic inhibitors of 5-lipoxygenase |
CA2643670A1 (en) | 2006-02-27 | 2007-08-30 | Sterix Limited | Diaryl compounds as non-steroidal inhibitors of 17-beta hydroxysteroid dehydrogenase and/or steroid sulphatase for the treatment of oestrogen-related diseases such as hormone dependent breast cancer |
US20090029949A1 (en) | 2006-05-25 | 2009-01-29 | Parrill-Baker Abby L | GPCR Ligands Identified by Computational Modeling |
WO2008024979A2 (en) | 2006-08-24 | 2008-02-28 | The Scripps Research Institute | Methods utilizing cell-signaling lysophospholipids |
US20080051372A1 (en) | 2006-08-24 | 2008-02-28 | The Scripps Research Institute | Methods utilizing cell-signaling lysophospholipids |
US20100143381A1 (en) | 2007-03-12 | 2010-06-10 | Andrew Tager | Lysophosphatidic acid receptor targeting for lung disease |
US9163091B2 (en) | 2007-05-30 | 2015-10-20 | Lpath, Inc. | Compositions and methods for binding lysophosphatidic acid |
WO2009011850A2 (en) * | 2007-07-16 | 2009-01-22 | Abbott Laboratories | Novel therapeutic compounds |
MX2010011754A (es) | 2008-05-05 | 2010-12-06 | Sanofi Aventis | Derivados de acido ciclopentanocarboxilico condensados sustituidos con acilamino y su uso como productos farmaceuticos. |
US8455499B2 (en) | 2008-12-11 | 2013-06-04 | Amira Pharmaceuticals, Inc. | Alkyne antagonists of lysophosphatidic acid receptors |
GB2466121B (en) | 2008-12-15 | 2010-12-08 | Amira Pharmaceuticals Inc | Antagonists of lysophosphatidic acid receptors |
GB2470833B (en) | 2009-06-03 | 2011-06-01 | Amira Pharmaceuticals Inc | Polycyclic antagonists of lysophosphatidic acid receptors |
EP2462128B1 (en) | 2009-08-04 | 2016-09-21 | Amira Pharmaceuticals, Inc. | Compounds as lysophosphatidic acid receptor antagonists |
GB2474748B (en) | 2009-10-01 | 2011-10-12 | Amira Pharmaceuticals Inc | Polycyclic compounds as lysophosphatidic acid receptor antagonists |
GB2474120B (en) | 2009-10-01 | 2011-12-21 | Amira Pharmaceuticals Inc | Compounds as Lysophosphatidic acid receptor antagonists |
-
2010
- 2010-08-03 EP EP10807045.9A patent/EP2462128B1/en not_active Not-in-force
- 2010-08-03 JP JP2012523709A patent/JP2013501064A/ja active Pending
- 2010-08-03 CN CN2010800429638A patent/CN102574822A/zh active Pending
- 2010-08-03 WO PCT/US2010/044284 patent/WO2011017350A2/en active Application Filing
- 2010-08-03 US US13/388,502 patent/US8592402B2/en active Active
- 2010-08-03 IN IN754DEN2012 patent/IN2012DN00754A/en unknown
Also Published As
Publication number | Publication date |
---|---|
WO2011017350A3 (en) | 2011-06-30 |
CN102574822A (zh) | 2012-07-11 |
EP2462128A2 (en) | 2012-06-13 |
US20120196839A1 (en) | 2012-08-02 |
WO2011017350A2 (en) | 2011-02-10 |
US8592402B2 (en) | 2013-11-26 |
EP2462128A4 (en) | 2012-10-03 |
JP2013501064A (ja) | 2013-01-10 |
EP2462128B1 (en) | 2016-09-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IN2012DN02177A (nl) | ||
IN2012DN02730A (nl) | ||
IN2012DN00754A (nl) | ||
MY163055A (en) | Polycyclic antagonists of lysophosphatidic acid receptors | |
MX2013006040A (es) | Antagonistas del receptor de acido lisofosfatidico y su uso en el tratamiento de fibrosis. | |
PH12020550450A1 (en) | Certain chemical entities, compositions and methods | |
WO2010077882A3 (en) | Antagonists of lysophosphatidic acid receptors | |
PH12015501737A1 (en) | Androgen receptor modulators and uses thereof | |
MX2013002975A (es) | Moduladores de receptores de estrogenos y usos de los mismos. | |
WO2010068775A3 (en) | Alkyne antagonists of lysophosphatidic acid receptors | |
PH12014501351A1 (en) | Fluorinated estrogen receptor modulators and uses thereof | |
PH12014502095A1 (en) | Estrogen receptor modulators and uses thereof | |
WO2012024620A3 (en) | Autotaxin inhibitors and uses thereof | |
UA98839C2 (en) | N,n-disubstituted aminoalkylbiphenyl antagonists of prostaglandin d2 receptors | |
WO2011156518A3 (en) | Estrogen receptor modulators and uses thereof | |
GB0906579D0 (en) | Pharmaceuticals, compositions and methods of making and using the same | |
MY162604A (en) | Heterocyclic compounds and uses thereof | |
IN2012DN02471A (nl) | ||
TN2010000463A1 (en) | Compositions and methods for preparing and using same |